The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | CAR T-cell therapy in multiple myeloma: highlights from ASH 2025
In this video, Xuzhao Zhang, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China, summarizes key updates in CAR T-cell therapy for multiple myeloma presented at the 2025 ASH Annual Meeting. Prof. Zhang reviews early efficacy data for dual CD19/BCMA-targeted CAR T-cell therapy and real-world safety outcomes for ciltacabtagene autoleucel (cilta-cel). He also discusses the impact of frailty on CAR T-cell efficacy and toxicity, and highlights strategies to optimize patient selection, supportive care, and post-CAR-T management to improve outcomes in high-risk patients. This video is provided courtesy of TalkMED, in collaboration with Magdalen Medical Publishing (MMP).
These works are protected by copyright laws and treaties around the world. All rights are reserved.
